SAN CARLOS, Calif.-- October 14, 2026 -- Altay Therapeutics, Inc., a biotechnology company developing novel small molecule inhibitors of transcription factors, today announced the completion of a $37 million Series...
FDA provides clearance of TyRx antibacterial patch for soft tissue repair
News | 04. 27. 2010
TYRX
TYRX, Inc. announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance to market AIGISRx® ST , its antibacterial product for the surgical repair of damaged or ruptured soft tissue.
